Shannon Campbell
Fortune : 19 680 $ au 31/05/2026
Fortune : 19 680 $ au 31/05/2026
Shannon Campbell is currently Director at Zentalis Pharmaceuticals, Inc. since 2026 and Independent Director at Black Diamond Therapeutics, Inc. since 2024.
Formerly, Ms. Campbell was Chief Commercial Officer & Executive VP at Merus NV from 2022 to 2026 and Vice President & General Manager-Oncology at Bayer HealthCare Pharmaceuticals, Inc. from 2005 to 2017.
Education includes undergraduate studies at Ithaca College.
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 27/04/2026 | 8 865 ( 0,02% ) | 19 680 $ | 31/05/2026 |
| Sociétés | Poste | Début |
|---|---|---|
| BLACK DIAMOND THERAPEUTICS, INC. | Directeur/Membre du Conseil | 10/04/2024 |
| ZENTALIS PHARMACEUTICALS, INC. | Directeur/Membre du Conseil | 22/05/2026 |
| Sociétés | Poste | Fin |
|---|---|---|
| MERUS N.V. | Corporate Officer/Principal | 01/01/2026 |
Bayer HealthCare Pharmaceuticals, Inc.
Bayer HealthCare Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Manufactures pharmaceutical drugs | Corporate Officer/Principal | 01/01/2017 |
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
| Entreprise privées | 5 |
|---|---|
Ithaca College
Ithaca College Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Bayer HealthCare Pharmaceuticals, Inc.
Bayer HealthCare Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Manufactures pharmaceutical drugs | Health Technology |
Merus NV
Merus NV BiotechnologyHealth Technology Discovers and develops therapeutics for cancer treatment | Health Technology |
Black Diamond Therapeutics, Inc.
Black Diamond Therapeutics, Inc. BiotechnologyHealth Technology Discovers and develops precision medicines for cancer | Health Technology |
Zentalis Pharmaceuticals, Inc.
Zentalis Pharmaceuticals, Inc. BiotechnologyHealth Technology Develops clinical therapeutics for targeting fundamental cancer pathways | Health Technology |
Sélectionnez votre édition
Toutes les informations financières adaptées au niveau national